Briquilimab

Generic Name: Briquilimab

Drug Type: Biotech

CAS Number: 2574591-89-0

Unique Ingredient Identifier: QWX84D0DRC

Background: Briquilimab is a humanized aglycosylated IgG1 kappa monoclonal antibody targeting CD117 (cKit).

Clinical Trials

A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria Trials

Phase 2

Conditions: Urticaria Chronic

Interventions: Drug: Briquilimab

First Posted Date: 2024-12-16

Last Posted Date: 2025-05-16

Lead Sponsor: Jasper Therapeutics, Inc.

Target Recruit Count: 90

Registration Number: NCT06736262

Locations: 🇺🇸
Investigative Site 116, Tampa, Florida, United States
🇺🇸
Investigative Site 109, Boise, Idaho, United States
🇺🇸
Investigative Site 124, Normal, Illinois, United States

and more 15 locations

A Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Briquilimab in Participants with Allergic Asthma

Phase 1

Recruiting

Conditions: Allergic Asthma

Interventions: Other: Placebo Comparator
Drug: Briquilimab

First Posted Date: 2024-09-19

Last Posted Date: 2025-03-26

Lead Sponsor: Jasper Therapeutics, Inc.

Target Recruit Count: 30

Registration Number: NCT06592768

Locations: 🇨🇦
McMaster University, Hamilton, Ontario, Canada
🇨🇦
University of Calgary, Calgary, Alberta, Canada
🇨🇦
University of Alberta, Edmonton, Alberta, Canada

and more 3 locations

A Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients With Chronic Inducible Urticaria (CIndU) Who Remain Symptomatic Despite Treatment With H1- Antihistamines

Phase 1

Active, not recruiting

Conditions: Chronic Inducible Urticaria

Interventions: Drug: Briquilimab

First Posted Date: 2024-04-09

Last Posted Date: 2025-05-21

Lead Sponsor: Jasper Therapeutics, Inc.

Target Recruit Count: 27

Registration Number: NCT06353971

Locations: 🇩🇪
Charité - University Clinic Berlin, Berlin, Germany
🇩🇪
University Hospital Dresden, Dresden, Germany
🇩🇪
Medical University Hannover, Hannover, Germany

and more 3 locations

Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients with Chronic Spontaneous Urticaria (CSU)

Phase 1

Recruiting

Conditions: Chronic Spontaneous Urticaria

Interventions: Drug: Briquilimab
Other: Placebo

First Posted Date: 2023-12-08

Last Posted Date: 2025-02-04

Lead Sponsor: Jasper Therapeutics, Inc.

Target Recruit Count: 80

Registration Number: NCT06162728

Locations: 🇩🇪
Site 202, Marburg, Germany
🇩🇪
Site 210, München, Germany
🇩🇪
Site 204, Münster, Germany

and more 29 locations

Allogeneic Hematopoietic Stem Cell Transplantation With Briquilimab-Based Conditioning in Participants With GATA2 Deficiency

Phase 2

Recruiting

Conditions: GATA2
Immunodeficiency

Interventions: Drug: Mycophenolate Mofetil
Drug: Tacrolimus
Drug: Post-Transplant Cyclophosphamide
Radiation: Total Body Irradiation
Procedure: Hematopoietic Cell Transplant
Drug: Briquilimab
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2023-06-18

Last Posted Date: 2025-05-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT05907746

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

JSP191 (briquilimab) in Subjects with LR-MDS

Phase 1

Terminated

Conditions: Lower-risk Myelodysplastic Syndrome

Interventions: Drug: JSP191

First Posted Date: 2023-06-15

Last Posted Date: 2025-02-27

Lead Sponsor: Jasper Therapeutics, Inc.

Target Recruit Count: 6

Registration Number: NCT05903274

Locations: 🇺🇸
Memorial Healthcare System, Hollywood, Florida, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Study to Assess the Use of JSP191 in Matched Unrelated Donor Transplantation for Chronic Granulomatous Disease (CGD)

Early Phase 1

Recruiting

Conditions: Chronic Granulomatous Disease
CGD

Interventions: Biological: JSP191

First Posted Date: 2022-11-01

Last Posted Date: 2025-04-03

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 30

Registration Number: NCT05600907

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia

Phase 1

Active, not recruiting

Conditions: Sickle Cell Anemia
Beta Thalassemia

Interventions: Radiation: TBI
Drug: Hydroxyurea
Biological: briquilimab
Drug: Filgrastim (G-CSF)
Drug: Sirolimus
Biological: Alemtuzumab
Drug: Plerixafor

First Posted Date: 2022-05-03

Last Posted Date: 2025-03-26

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 40

Registration Number: NCT05357482

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Depleted Donor Stem Cell Transplant in Children and Adults With Fanconi Anemia After Being Conditioned With a Regimen Containing Briquilimab

Phase 1

Recruiting

Conditions: Fanconi Anemia

Interventions: Drug: JSP191
Device: CliniMACS Prodigy System
Biological: Depleted Stem Cell Transplant
Biological: Rabbit Anti-Thymoglobulin (rATG)
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Rituximab

First Posted Date: 2021-03-05

Last Posted Date: 2025-04-06

Lead Sponsor: Porteus, Matthew, MD

Target Recruit Count: 12

Registration Number: NCT04784052

Locations: 🇺🇸
Stanford University, Stanford, California, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy